These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29682790)

  • 1. Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada.
    Minhas R; Tadrous M; Elterman D; Gomes T
    Neurourol Urodyn; 2018 Jun; 37(5):1693-1700. PubMed ID: 29682790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
    Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
    J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study.
    Park JS; Choi SB; Jang WS; Kim J; Ham WS
    Eur Urol Focus; 2024 Mar; 10(2):306-314. PubMed ID: 38388215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug therapy for an overactive bladder.
    Thiagamoorthy G; Cardozo L; Srikrishna S
    Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
    [No Abstract]   [Full Text] [Related]  

  • 7. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists.
    Okui N
    World J Urol; 2019 Nov; 37(11):2459-2466. PubMed ID: 30687908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
    Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
    Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
    Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?
    Fogaing C; Mossa AH; Campeau L
    Curr Urol Rep; 2020 Oct; 21(12):49. PubMed ID: 33090278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy - An Addendum.
    Geoffrion R
    J Obstet Gynaecol Can; 2017 Dec; 39(12):1221-1229. PubMed ID: 28986184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary incontinence: Patient-reported outcome measures favour use of mirabegron in patients with OAB.
    Sidaway P
    Nat Rev Urol; 2015 Nov; 12(11):593. PubMed ID: 26345211
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
    Kobayashi M; Nukui A; Kamai T
    Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia.
    Mullen GR; Kaplan SA
    Curr Urol Rep; 2021 Jan; 22(1):5. PubMed ID: 33411109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N
    Geoffrion R
    J Obstet Gynaecol Can; 2017 Dec; 39(12):1230-1239. PubMed ID: 28986183
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.